Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of “Hold” by Analysts

Oncobiologics, Inc. (NASDAQ:OTLK) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.50.

Several equities research analysts have recently weighed in on OTLK shares. Ascendiant Capital Markets increased their price target on Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a research note on Monday, December 29th. Chardan Capital reiterated a “neutral” rating on shares of Oncobiologics in a report on Wednesday. HC Wainwright reissued a “neutral” rating on shares of Oncobiologics in a research note on Wednesday. Finally, Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd.

Institutional Trading of Oncobiologics

A number of hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its holdings in shares of Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares during the last quarter. AQR Capital Management LLC increased its position in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after buying an additional 21,941 shares during the last quarter. 11.20% of the stock is owned by hedge funds and other institutional investors.

Oncobiologics Price Performance

NASDAQ:OTLK opened at $0.41 on Friday. The firm has a market capitalization of $34.32 million, a price-to-earnings ratio of -0.16 and a beta of 0.10. The business has a 50 day simple moving average of $0.90 and a 200-day simple moving average of $1.31. Oncobiologics has a 1 year low of $0.38 and a 1 year high of $3.39.

Oncobiologics (NASDAQ:OTLK) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The company had revenue of ($1.21) million during the quarter, compared to the consensus estimate of $3.14 million. As a group, analysts expect that Oncobiologics will post -2.27 earnings per share for the current fiscal year.

Oncobiologics News Summary

Here are the key news stories impacting Oncobiologics this week:

• Positive Sentiment: Brookline Capital Acquisition raised its Q4 2026 EPS estimate for OTLK to ($0.18) from ($0.22), narrowing the expected quarterly loss — a modest positive signal that one shop sees slightly better near-term performance.
• Neutral Sentiment: HC Wainwright reiterated a “Neutral” rating on Oncobiologics while publishing updated quarterly/annual estimates; the firm remains cautious but did not upgrade or downgrade the stock. HC Wainwright Reaffirms “Neutral” Rating for Oncobiologics (NASDAQ:OTLK)
• Neutral Sentiment: Chardan Capital reiterated its “Neutral” rating on OTLK, signaling no near-term change in analyst stance despite the earnings miss and estimate revisions. Chardan Capital Reiterates Neutral Rating for Oncobiologics (NASDAQ:OTLK)
• Negative Sentiment: HC Wainwright cut FY2026 estimates significantly (FY2026 EPS to ($0.42) from ($0.28)) and trimmed FY2027 to ($0.21) from ($0.19), and nudged Q4 2026 to a larger expected loss — these downward revisions signal weaker near-term profitability expectations and add selling pressure.
• Negative Sentiment: Brookline Capital Acquisition lowered multiple 2026 quarterly and full‑year EPS forecasts (e.g., FY2026 now ($0.79) vs. prior ($0.74); Q2/Q3 2026 also reduced), indicating broader analyst downside revisions across the board.
• Negative Sentiment: Oncobiologics’ recent reported miss (Feb. 17: EPS ($0.22) vs est. ($0.17); revenue sharply below expectations) remains the primary near-term catalyst weighing on the stock—analyst cuts followed the miss and are likely driving continued downward price pressure.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.